Results from a Phase 1b clinical trial indicate that Kyprolis in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone is effective and safe for re­lapsed multiple myeloma patients.

Moreover, at the higher doses of Kyprolis and Revlimid tested during the trial, a greater share of patients responded to treat­ment than was the case in a trial testing Revlimid, Velcade, and dexa­meth­a­sone in a similar patient population.

In addi­tion, noticeably fewer cases of periph­eral neu­rop­athy – that is, pain, tingling, or loss of …

The results of a recent French Phase 2 study investigating two Pomalyst (poma­lido­mide) dosing schedules have been published.

The response, survival, and safety data from the study are in line with the results of other Pomalyst trials that have been made public over the past year or two.

In particular, the trial results indicate that the combination of Pomalyst plus low-dose dexamethasone is effective in multiple myeloma patients who have re­lapsed from, or are resistant to treatment with, …

Results of a small Phase 2 study may lead to improved outcomes for newly diagnosed patients who are unable to achieve a deep response with a Revlimid- or thalidomide-based initial therapy.

The study indicates that follow-on treatment with a Velcade-based regimen can noticeably deepen responses in these patients.

“We were certainly pleased to see that we were able to confirm our hypothesis that offering Velcade-containing, non-cross-resistant combinations to patients whose response had stalled after [Revlimid- or thalidomide-] based therapy can …

A new study provides the first detailed look at Kyprolis when it is used in multiple myeloma patients with kidney damage.

The focus of the study is on determining how Kyprolis (car­filz­o­mib) is processed in the bodies of myeloma patients and, in particular, if the drug is processed differently depending on how much kidney damage a patient has.

In addi­tion, the study in­ves­ti­gates whether kidney damage affects how often patients experience side effects when treated with Kyprolis.

Based on the …

The results of a recent retrospective analysis show that long-term treat­ment with the combination of Revlimid, clarithromycin (Biaxin), and dexa­methasone – commonly abbreviated "BiRd" – is effective and safe in newly diagnosed myeloma patients.

Furthermore, the study did not find any significant association between long-term Revlimid (lenalidomide) therapy and an increased risk of developing secondary cancers.

“We did expect these results. It was our sense from following patients who have been treated with lena­lido­mide [Revlimid] long-term and have not received any genotoxic therapy …

The results of a recent retrospective study show that the use of novel agents for the treatment of multiple myeloma may not have a negative impact on subse­quent stem cell collection and transplantation.

The study's results stand in contrast to previous research that has suggested that Revlimid, one of the most commonly used novel agents, may have a nega­tive effect on stem cell collection.

Factors in the current study that were found to be associated with stem cell col­lection failure …

Results from a recent study indicate that the two leading models for classifying smoldering myeloma patients based on their risk of disease progression disagree significantly more often than they agree.

The two models were developed independently by researchers at the Mayo Clinic and the Spanish 'PETHEMA' working group.

Given the results of their comparison, the authors of the current study argue that further studies are needed to define a more broadly applicable set of criteria to assess a smoldering myeloma …